BioSpace News Archive

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; “NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today financial results for the quarter and full fiscal year ended September 30, 2021.

I-Mab (the “Company”) (Nasdaq: IMAB), today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved the IND submission for the initiation of a phase 1 clinical study of the bispecific antibody TJ-CD4B (also known as ABL111).

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for spesolimab for the treatment of generalized pustular psoriasis (GPP) flares.

IACTA Pharmaceuticals, Inc. (“IACTA”), an innovation leader in ophthalmic therapeutics, and TALLC Corporation Inc. (“TALLC”), a pioneering ophthalmology company focused on the growing unmet needs of patients with corneal and retinal conditions, today announced that they are entering into a strategic collaboration and licensing agreement.

Spectrum Solutions, LLC today announced that COVID-19 RT-PCR saliva tests using the Spectrum SDNA-1000 for bio-sample collection will also successfully be able to detect the additional Omicron viral variant and its mutations.

1910 Genetics today announced that Jennifer Leeds, Ph.D., will join as an independent member of the company’s Board of Directors.

Twist Bioscience Corporation today announced that synthetic RNA positive controls are now available for the SARS-CoV-2 Omicron (B.1.1.529/BA.1) variants first identified in South Africa.

Lisen Imprinting Diagnostics announces an innovative and ground-breaking epigenetics-based diagnostic solution for early lung cancer detection.

Alcami Corporation, a leading pharmaceutical and biotech contract development and manufacturing organization, announced it has completed the acquisition of Masy Systems Inc., a preferred provider of cGMP Biostorage and pharma support services.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), today announced that the Data Safety Monitoring Board (DSMB) for the Phase 3 TOGETHER study has conducted a second interim futility analysis and recommended continuation of the study.